Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Scinai Immunotherapeutics Ltd. SCNI NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • IL • USD

SharesGrow Score
57/100
2/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Scinai Immunotherapeutics Ltd. (SCNI) is a Biotechnology company in the Healthcare sector, currently trading at $0.61. It has a SharesGrow Score of 54/100, indicating a mixed investment profile with 2 out of 7 criteria passed.

Valuation: SCNI trades at a trailing Price-to-Earnings (P/E) of -0.1 (S&P 500 average ~25).

Financials: revenue is $658,000, +0%/yr average growth. Net income is $5M, growing at +63.7%/yr. Net profit margin is 728.9% (strong). Gross margin is -88.1% (+0 pp trend).

Balance sheet: total debt is $2M against $10M equity (Debt-to-Equity (D/E) ratio 0.21, conservative). Current ratio is 1.32 (adequate). Debt-to-assets is 15.5%. Total assets: $13M.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 100/100 (Pass), Past 25/100 (Fail), Health 50/100 (Partial), Moat 11/100 (Fail), Future ?/100 (Fail), Income 100/100 (Pass).

SCNI SharesGrow Score Overview

57/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 100/100
Financials — average growth
PAST 25/100
strong — trend
HEALTH 50/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 11/100
Gross margin is + market cap
FUTURE 0/100
Analyst outlook — as buy
INCOME 100/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — SCNI

—
VALUE N/A
N/A
No analyst coverage available for this stock.
✓
GROWTH Pass
100/100
SCNI: +0%/yr revenue is, +63.7%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
✗
PAST Fail
25/100
SCNI: 1 / 4 years profitable. weak. Score = 1 / 4 × 100. ≥ 80 = Pass.
View details →
~
HEALTH Partial
50/100
Balance sheet SCNI: Debt-to-Equity (D/E) ratio 0.21 (conservative), Current ratio is 1.32 (adequate). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
11/100
SCNI: Gross margin is -88.1% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 11/100. ≥ 70 = Pass.
View details →
—
FUTURE N/A
N/A
No analyst coverage available for this stock.
✓
INCOME Pass
100/100
SCNI: Net profit margin is 728.9%. strong (≥30%). Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range0.55-6.18
Volume10.02K
Avg Volume (30D)54.3K
Market Cap$802.37K
Beta (1Y)1.89
Share Statistics
Shares Outstanding$806.37K
IPO Date2015-05-11
Employees31
CEOAmir Reichman
Financial Highlights & Ratios
Revenue (TTM)$658K
Gross Profit$-580K
EBITDA$7.87M
Net Income$4.8M
Operating Income$-8.64M
Total Cash$1.96M
Total Debt$2.09M
Net Debt$122K
Total Assets$13.45M
Price / Sales (P/S)1.22
Analyst Forecast
Company Info
CountryIL
ExchangeNASDAQ Capital Marke
CurrencyUSD
ISINUS09073Q3039

Price Chart

Track all markets on TradingView
SCNI
Scinai Immunotherapeutics Ltd. ↗  ·  NASDAQ Capital Marke
Healthcare • Biotechnology
0.55 52WK RANGE 6.18

People Also View

JSPR
JSPR
Jasper Therapeutics, Inc.
$1.05
+12.61%
 SLRX
SLRX
Salarius Pharmaceuticals, Inc.
$0.84
+29.23%
 INDP
INDP
Indaptus Therapeutics, Inc.
$2.71
+16.31%
 REVB
REVB
Revelation Biosciences, Inc.
$1.26
+5.00%
 ONCO
ONCO
Onconetix, Inc.
$0.76
-16.32%
 AZTR
AZTR
Azitra, Inc.
$0.22
+1.76%
 ENVB
ENVB
Enveric Biosciences, Inc.
$2.03
+4.10%
 SLXN
SLXN
Silexion Therapeutics Ltd.
$1.02
-1.92%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message